Impact of chronological age on efficacy and safety of fluoropyrimidine plus bevacizumab in older non-frail patients with metastatic colorectal cancer: a combined analysis of individual data from two phase II studies of patients aged >75 years.
Toshikazu MoriwakiTomohiro NishinaYoshinori SakaiYoshiyuki YamamotoMitsuo ShimadaHiroyasu IshidaKenji AmagaiMikio SatoShinji EndoYuji NegoroHidekazu KuramochiTadamichi DendaYukimasa HatachiKazuto IkezawaGo NakajimaYoshiaki BandoAkihito TsujiYuji YamamotoMasamitsu MorimotoKazuma KobayashiIchinosuke HyodoPublished in: Japanese journal of clinical oncology (2022)
The efficacy of fluoropyrimidine plus bevacizumab was age-independent in patients with metastatic colorectal cancer aged ≥75 years, and attention should be paid to non-hematologic adverse events as age increases.
Keyphrases
- metastatic colorectal cancer
- phase ii
- end stage renal disease
- clinical trial
- newly diagnosed
- ejection fraction
- chronic kidney disease
- open label
- peritoneal dialysis
- prognostic factors
- working memory
- randomized controlled trial
- electronic health record
- machine learning
- big data
- patient reported outcomes
- middle aged
- placebo controlled
- data analysis